CATALYST PHARMACEUTICALS, INC. 4

Chief HR Officer Gregg Russo disposed of his Catalyst Pharmaceuticals equity (common shares, stock options, and RSUs) for cash worth roughly $0.75 million in connection with the Angelini Pharma S.p.A. acquisition at $31.50 per share.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chief HR Officer Gregg Russo had all of his equity awards cashed out in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. at $31.50 per share. This included 476 shares of common stock sold for cash at $31.50 per share (about $15,000), and the cancellation for cash of multiple option grants and RSUs: (i) stock options for 15,000 shares at a $15.51 strike (cash value ≈ $239,850), 6,957 shares at $22.90 (≈ $59,346), 20,349 shares at $23.26 (≈ $167,476), and 20,531 shares at $22.77 (≈ $179,516), each converted into a cash payment equal to $31.50 minus the strike price, multiplied by the shares; and (ii) RSUs for 2,752 shares and 6,197 shares (≈ $86,100 total) converted into cash at $31.50 per share. All options and RSUs vested in full and were disposed of as part of the merger, leaving Russo with no remaining equity ownership in Catalyst. The aggregate transaction value is approximately $747,000, and the activity is purely merger-related rather than open‑market trading.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000181

Alert Tier

6